tbuckley/cabot-search huggingface dataset:
Pharmacology of Intestinal Inflammation and Repair
Authors: Céline Deraison, Nathalie Vergnolle
Journal: The Annual Review of Pharmacology and Toxicology (2025)

Chronic inflammation is a common trait in the pathogenesis of several diseases of the gut, including inflammatory bowel disease and celiac disease. Control of the inflammatory response is crucial in these pathologies to avoid tissue destruction and loss of intestinal function. Over the last 50 years, the identification of the mechanisms and mediators involved in the acute phase of the inflammatory response, which is characterized by massive leukocyte recruitment, has led to a number of therapeutic options. New drugs targeting inflammatory flares are still under development. However, interest on the other end of the spectrum-the resolution and repair phases-has emerged, as promoting tissue functional repair may maintain remission and counteract the chronicity of the disease. This review aims to discuss the current and future pharmacological approaches to the treatment of chronic intestinal inflammation and the restoration of functional tissues.
Mutant KRAS and CK2 Cooperatively Stimulate SLC16A3 Activity to Drive Intrahepatic Cholangiocarcinoma Progression
Authors: Ran Chen, Cuihong Ma, Haoran Qian, Xinyu Xie, Yuxue Zhang, Dayun Lu, Shunjie Hu, Mao Zhang, Fen Liu, Yunhao Zou, Qiang Gao, Hu Zhou, Hailong Liu, Moubin Lin, Gaoxiang Ge, Daming Gao
Journal: Cancer Research (2025)

Abstract Intrahepatic cholangiocarcinoma (iCCA) is a lethal malignancy affecting the liver and biliary system. Enhanced understanding of the pathogenic mechanisms underlying iCCA tumorigenesis and the discovery of appropriate therapeutic targets are imperative to improve patient outcomes. Here, we investigated the functions and regulations of solute carrier family 16 member 3 (SLC16A3), which has been reported to be a biomarker of poor prognosis in iCCA. High SLC16A3 expression was enriched in KRAS-mutated iCCA tumors, and mutant KRAS elevated SLC16A3 expression via the PI3K/AKT/mTORC1/HIF1α pathway. SLC16A3 not only enhanced glycolysis but also induced epigenetic reprogramming to regulate iCCA progression. Phosphorylation of SLC16A3 at S436 (p-S436) was vital for its oncogenic function and was linked to iCCA progression. Casein kinase 2 (CK2) directly phosphorylated SLC16A3 at S436, and CK2 inhibition with CX-4945 (silmitasertib) reduced the growth of KRAS-mutated iCCA tumor xenografts and patient-derived organoids. Together, this study provides valuable insights into the diverse functions of SLC16A3 in iCCA and comprehensively elucidates the upstream regulatory mechanisms, providing potential therapeutic strategies for iCCA patients with KRAS mutations.
68Ga-FAPI-04 Outperforms 18F-FDG in Detecting Lesions for Primary Leiomyosarcoma of Bone
Authors: Yaqun Jiang, Yueli Tian, Yong He
Journal: Clinical Nuclear Medicine (2025)

Abstract Primary leiomyosarcoma of bone (PLB) is an ultrarare tumor, characterized by its aggressive clinical behavior, high heterogeneity, and dismal prognosis. Here, we present the 68 Ga-FAPI-04 and 18 F-FDG PET/CT findings in a case of PLB affecting the left femur. FAPI PET/CT showed more bone lesions and higher uptake in the multiple metastatic lesions compared with FDG PET/CT. More interestingly, FAPI PET/CT could clearly detect the tumor embolus on the left common femoral artery, which was negative on FDG. This case suggests that FAPI PET/CT is a promising method for the primary diagnosis and staging of PLB.
Enhanced BBB penetration and microglia-targeting nanomodulator for the two-pronged modulation of chronically activated microglia-mediated neuroinflammation in Alzheimer’s disease
Authors: Ya Wei, Xue Xia, Xiaorong Wang, Wenqin Yang, Siqin He, Lulu Wang, Yongke Chen, Yang Zhou, Feng Chen, Hanmei Li, Fu Peng, Guobo Li, Zheng Xu, Jintao Fu, Huile Gao
Journal: Acta Pharmaceutica Sinica B (2025)

Intervention in chronically activated microglia-mediated neuroinflammation is a novel approach to treat Alzheimer's disease (AD). The low permeability of the blood‒brain barrier (BBB) and non-selective distribution in the brain severely restrict AD drugs' disease-modifying efficacy. Here, an immunosuppressant TREM2-lowing antisense oligonucleotides (ASOs) and resveratrol co-loaded cationic liposome is developed as an immune reprogramming nanomodulator modified by acid-cleavable BBB-targeting peptide and microglia-targeting peptide (Res@TcMNP/ASO) for AD management. Res@TcMNP/ASO can enter brain endothelial cells via D-T7 peptides. Then D-T7 undergoes an acid-responsive cleavage, facilitating the escape of Res@MNP/ASO from endo/lysosomes to cross the BBB. The detached Res@MNP/ASO specifically targets M1-phenotype microglia via exposed MG1 peptides to prompt the simultaneous delivery of two drugs into activated microglia. This nanomodulator can not only restore the immune function of microglia through TREM2-lowing ASO but also mitigate the immune stimulation to microglia caused by reactive oxygen species (ROS) through resveratrol, thereby synergistically inhibiting the chronic activation of microglia to alleviate neuroinflammation in AD. Our results indicate that this combination treatment can achieve significant behavioral and cognitive improvements in late APP/PS1 mice.
Brain Microenvironment-Remodeling Nanomedicine Improves Cerebral Glucose Metabolism, Mitochondrial Activity and Synaptic Function in A Mouse Model of Alzheimer’s Disease
Authors: Elliya Park, Chunsheng He, Azhar Z Abbasi, Meng Tian, Shudi Huang, Liting Wang, John Georgiou, Graham L Collingridge, Paul E Fraser, Jeffrey T Henderson, Xiao Yu Wu
Journal: Biomaterials (2025)
Photochemical bomb: Precision nuclear targeting to activate cGAS-STING pathway for enhanced bladder cancer immunotherapy
Authors: Dexiang Feng, Xiaoying Kang, He Wang, Zhangxin He, Haodong Xu, Yue Li, Aohua Fan, Hongbo Xu, Yuan Zhang, Jianwen Song, Jianquan Hou, Ji Qi, Weijie Zhang
Journal: Biomaterials (2025)
A Comprehensive Atlas of AAV Tropism in the Mouse
Authors: Christopher J Walkey, Kathy J Snow, Jote Bulcha, Aaron R Cox, Alexa E Martinez, M Cecilia Ljungberg, Denise G Lanza, Marco De Giorgi, Marcel A Chuecos, Michele Alves-Bezerra, Carlos Flores Suarez, Sean M Hartig, Susan G Hilsenbeck, Chih-Wei Hsu, Ethan Saville, Yaned Gaitan, Jeff Duryea, Seth Hannigan, Mary E Dickinson, Oleg Mirochnitchenko, Dan Wang, Cathleen M Lutz, Jason D Heaney, Guangping Gao, Stephen A Murray, William R Lagor
Journal: Molecular Therapy (2025)
GITRL enhances cytotoxicity and persistence of CAR-T cells in cancer therapy
Authors: Binghe Tan, Chuntian Tu, Hao Xiong, Yongqian Xu, Xiujuan Shi, Xiaolin Zhang, Ruijie Yang, Na Zhang, Boxu Lin, Mingyao Liu, Juliang Qin, Bing Du
Journal: Molecular Therapy (2025)
TRAF1 promotes osteoclastogenesis by enhancing metabolic adaptation to oxidative phosphorylation in an AKT-dependent manner
Authors: Honglei Kang, Renpeng Peng, Yiming Dong, Fuben Liao, Meipeng Zhu, Pengju Wang, Shi-An Hu, Peixuan Hu, Jia Wang, Zheming Liu, Kehan Song, Feng Li
Journal: Molecular Therapy (2025)
A 211At-labelled mGluR1 inhibitor induces cancer senescence to elicit long-lasting anti-tumor efficacy
Authors: Lin Xie, Lulu Zhang, Kuan Hu, Masayuki Hanyu, Yiding Zhang, Masayuki Fujinaga, Katsuyuki Minegishi, Takayuki Ohkubo, Kotaro Nagatsu, Cuiping Jiang, Takashi Shimokawa, Kazuma Ashisuke, Noriyuki Okonogi, Shigeru Yamada, Feng Wang, Rui Wang, Ming-Rong Zhang
Journal: Cell Reports Medicine (2025)
Patient perspectives on the lived experience of prurigo nodularis: a qualitative approach
Authors: Anjali J D'Amiano, Vrinda Madan, Emily Ma, Connie Cai, Bethlehem Lulseged, Deepa Ravindra, Jack Kollings, Viviane Liao, Shawn G Kwatra
Journal: Journal of the American Academy of Dermatology (2025)
Flexible, Surface-lighting MicroLED Skin Patch for Multiple Human Skincare
Authors: Jae Hee Lee, Min Seo Kim, Seung Hyung Lee, Sang Hyun Park, Ki Yun Nam, Jaehun An, Myoung Song, Ki Soo Kim, Sang Ho Oh, Taek-Soo Kim, Keon Jae Lee
Journal: Biomaterials (2025)
Bioprosthetic vs Mechanical Aortic Valve Replacement in Patients 40-75 Years
Authors: Michael E Bowdish, J Hunter Mehaffey, Shu-Ching Chang, Patrick T O'Gara, Michael J Mack, Andrew B Goldstone, Joanna Chikwe, A Marc Gillinov, Changfu Wu, Gregory P Fontana, Joseph E Bavaria, Chris S Malaisrie, Tsuyoshi Kaneko, Ibrahim S Sultan, Moritz C Wyler von Ballmoos, Kathrine B Harrington, Jeffrey P Jacobs, Vinod H Thourani, Wilson Y Szeto, Joseph F Sabik, Robert H Habib, Vinay Badhwar
Journal: Journal of the American College of Cardiology (2025)
A multicenter study of neurofibromatosis type 1 utilizing deep learning for whole body tumor identification
Authors: Cheng-Jiang Wei, Yan Tang, Yang-Bai Sun, Tie-Long Yang, Cheng Yan, Hui Liu, Jun Liu, Jing-Ning Huang, Ming-Han Wang, Zhen-Wei Yao, Ji-Long Yang, Zhi-Chao Wang, Qing-Feng Li
Journal: npj Digital Medicine (2025)
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
Authors: Thierry André, Elena Elez, Heinz-Josef Lenz, Lars Henrik Jensen, Yann Touchefeu, Eric Van Cutsem, Rocio Garcia-Carbonero, David Tougeron, Guillermo Ariel Mendez, Michael Schenker, Christelle de la Fouchardiere, Maria Luisa Limon, Takayuki Yoshino, Jin Li, Jose Luis Manzano Mozo, Laetitia Dahan, Giampaolo Tortora, Myriam Chalabi, Eray Goekkurt, Maria Ignez Braghiroli, Rohit Joshi, Timucin Cil, Francine Aubin, Elvis Cela, Tian Chen, Ming Lei, Lixian Jin, Steven I Blum, Sara Lonardi
Journal: The Lancet (2025)
Cuproplasia and cuproptosis, two sides of the coin
Authors: Kaizhong Lu, Chandra Sugiarto Wijaya, Qinghua Yao, Hongchuan Jin, Lifeng Feng
Journal: Cancer Communications (2025)

Abstract Copper is an essential micronutrient in the human body, mainly acting as a crucial cofactor required for a wide range of physiological processes across nearly all cell types. Recent advances revealed that tumor cells seize copper to fulfill their rapid proliferation, metastasis, immune evasion, and so on by reprogramming the copper regulatory network, defined as cuproplasia. Thus, targeting copper chelation to reduce copper levels has been considered a rational tumor therapy strategy. However, overloaded copper ions could be toxic, which leads to the aggregation of lipoylated mitochondrial proteins and the depletion of iron‐sulfur clusters, ultimately resulting in cell death, termed cuproptosis. Upon its discovery, cuproptosis has attracted great interest from oncologists, and targeting cuproptosis by copper ionophores exhibits as a potential anti‐tumor therapy. In this review, we present the underlying mechanisms involved in cuproplasia and cuproptosis. Additionally, we sum up the chemicals targeting either cuproplasia or cuproptosis for cancer therapy. Further attention should be paid to distinguishing cancer patients who are suitable for targeting cuproplasia or cuproptosis.
Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial
Authors: Scott Kopetz, Takayuki Yoshino, Eric Van Cutsem, Cathy Eng, Tae Won Kim, Harpreet Singh Wasan, Jayesh Desai, Fortunato Ciardiello, Rona Yaeger, Timothy S. Maughan, Elena Beyzarov, Xiaoxi Zhang, Graham Ferrier, Xiaosong Zhang, Josep Tabernero
Journal: Nature Medicine (2025)

Abstract Encorafenib + cetuximab (EC) is approved for previously treated BRAF V600E-mutant metastatic colorectal cancer (mCRC) based on the BEACON phase 3 study. Historically, first-line treatment of BRAF V600E-mutant mCRC with chemotherapy regimens has had limited efficacy. The phase 3 BREAKWATER study investigated EC+mFOLFOX6 versus standard of care (SOC) in patients with previously untreated BRAF V600E mCRC. The dual primary endpoint of progression-free survival is event driven; data were not mature at data cutoff. BREAKWATER met the other dual primary endpoint of objective response rate, demonstrating significant and clinically relevant improvement in objective response rate (EC+mFOLFOX6: 60.9%; SOC: 40.0%; odds ratio, 2.443; 95% confidence interval (CI): 1.403–4.253; 99.8% CI: 1.019–5.855; one-sided P = 0.0008). Median duration of response was 13.9 versus 11.1 months. At this first interim analysis of overall survival, the hazard ratio was 0.47 (95% CI: 0.318–0.691; repeated CI: 0.166–1.322). Serious adverse event rates were 37.7% versus 34.6%. The safety profiles were consistent with those known for each agent. BREAKWATER demonstrated a significantly improved response rate that was durable for first-line EC+mFOLFOX6 versus SOC in patients with BRAF V600E mCRC. ClinicalTrials.gov identifier: NCT04607421 .
Predictors of response to low-dose amitriptyline for irritable bowel syndrome and efficacy and tolerability according to subtype: post hoc analyses from the ATLANTIS trial
Authors: Alexandra Wright-Hughes, Pei-Loo Ow, Sarah L Alderson, Matthew J Ridd, Robbie Foy, Felicity L Bishop, Matthew Chaddock, Catherine Fernandez, Elspeth A Guthrie, Delia P Muir, Christopher A Taylor, Amanda J Farrin, Hazel A Everitt, Alexander C Ford
Journal: Gut (2025)

Background Low-dose amitriptyline, a tricyclic antidepressant (TCA), was superior to placebo for irritable bowel syndrome (IBS) in the AmitripTyline at Low-dose ANd Titrated for Irritable bowel syndrome as Second-line treatment (ATLANTIS) trial. Objective To perform post hoc analyses of ATLANTIS for predictors of response to, and tolerability of, a TCA. Design ATLANTIS randomised 463 adults with IBS to amitriptyline (232) or placebo (231). We examined the effect of baseline demographic and disease-related patient characteristics on response to amitriptyline and the effect of amitriptyline on individual symptoms and side effects by subtype. Results There was a quantitative difference in amitriptyline effectiveness in those ≥50 years vs &lt;50 on the IBS severity scoring system (IBS-SSS) (interaction p=0.048, mean difference in ≥50 years subgroup −46.5; 95% CI −74.2 to −18.8, p=0.0010), and subjective global assessment of relief (interaction p=0.068, OR in ≥50 years subgroup 2.59; 95% CI 1.47 to 4.55, p=0.0010), and those in the 70% most deprived areas of England compared with the 30% least deprived for a ≥30% improvement in abdominal pain (interaction p=0.021, OR in 70% most deprived subgroup 2.70; 95% CI 1.52 to 4.77, p=0.0007). Stronger treatment effects were seen in men, with higher Patient Health Questionnaire-12 scores, and with IBS with diarrhoea. Mean differences in individual IBS-SSS components favoured amitriptyline, and side effects were similar, across almost all IBS subtypes. Conclusion These exploratory analyses demonstrate there are unlikely to be deleterious effects of amitriptyline in any particular IBS subtype and could help identify patients in whom amitriptyline may be more effective. Trial registration number ISRCTN48075063 .
HemaScope: A Tool for Analyzing Single-cell and Spatial Transcriptomics Data of Hematopoietic Cells
Authors: Zhenyi Wang, Yuxin Miao, Hongjun Li, Wenyan Cheng, Minglei Shi, Lv Gang, Yating Zhu, Junyi Zhang, Tingting Tan, Jin Gu, Michael Q Zhang, Jianfeng Li, Hai Fang, Zhu Chen, Saijuan Chen
Journal: Genomics Proteomics & Bioinformatics (2025)

Single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics (ST) techniques hold great value in evaluating the heterogeneity and spatial characteristics of hematopoietic cells within tissues. These two techniques are highly complementary, with scRNA-seq offering single-cell resolution and ST retaining spatial information. However, there is an urgent demand for well-organized and user-friendly toolkits capable of handling single-cell and spatial information. Here, we present HemaScope, a specialized bioinformatics toolkit featuring modular designs to analyze scRNA-seq and ST data generated from hematopoietic cells. It enables users to perform quality control, basic analysis, cell atlas construction, cellular heterogeneity exploration, and dynamical examination on scRNA-seq data. Also, it can perform spatial analysis and microenvironment analysis on ST data. Meanwhile, HemaScope takes into consideration hematopoietic cell-specific features, including lineage affiliation evaluation, cell cycle prediction, and marker gene collection. To enhance the user experience, we have deployed the toolkit in user-friendly forms: HemaScopeR (an R package), HemaScopeCloud (a web server), HemaScopeDocker (a Docker image), and HemaScopeShiny (a graphical interface). In case studies, we employed it to construct a cell atlas of human bone marrow, analyze age-related changes, and identify acute myeloid leukemia cells in mice. Moreover, we characterized the microenvironments in angioimmunoblastic T cell lymphoma and primary central nervous system lymphoma, elucidating tumor boundaries. HemaScope is freely available at https://zhenyiwangthu.github.io/HemaScope_Tutorial/.
Original article: Efficacy and safety of single-dose suraxavir marboxil tablet in the treatment of acute uncomplicated influenza in adults: a multi-center, randomized, double-blind, placebo-controlled phase 2 clinical trial
Authors: Yeming Wang, Hong Wang, Dong Liu, Yan Ding, Min Zhang, Zuke Xiao, Xueqiang Jiang, Yanan Wu, Wei Zhang, Shuilin Sun, None Xuyan Chen, Weijie Zhang, Yuling Tang, Ming Jiang, Guoru Yang, Weihua Jia, Xifu Wang, Jianlin Tong, Lijun Suo, Yongpei Yu, Xiaoyan Yan, Zi Li, Xiyan Li, Prof Bin Cao
Journal: Clinical Microbiology and Infection (2025)
How to: share and reuse data - challenges and solutions from PrIMAVeRa project
Authors: Mariana Guedes, Almudena de la Serna Bazan, Elena Rubio-Martín, Lydia Barrera Pulido, Virginia Palomo, Alen Piljić, Quentin J Leclerc, Emmanuel Aris, Venanzio Vella, Asta Dambrauskienė, Julie V Robotham, Astrid Pérez, Nasreen Hassoun-Kheir, Marlieke E A de Kraker, Fabiana Arieti, Ruth Joanna Davis, Evelina Tacconelli, Elena Salamanca-Rivera, Jesús Rodríguez-Baño
Journal: Clinical Microbiology and Infection (2025)
Pharmacological blocking of microfibrillar-associated protein 4 reduces retinal neoangiogenesis and vascular leakage
Authors: Anders Schlosser, Bartosz Pilecki, Claire Allen, Andrew V Benest, Amy P Lynch, Jing Hua, Nikita Ved, Zoe Blackley, Thomas L Andersen, Dorle Hennig, Jonas H Graversen, Sören Möller, Sofie Skallerup, Maria Ormhøj, Clemens Lange, Hansjürgen T Agostini, Jakob Grauslund, Steffen Heegaard, Ivanka Dacheva, Michael Koss, Wenzheng Hu, Bibiana Iglesias, Matthew S Lawrence, Hans Christian Beck, Lasse Bach Steffensen, Nick S Laursen, Gregers R Andersen, Uffe Holmskov, David O Bates, Grith L Sorensen
Journal: Molecular Therapy (2025)
A Nano-Enabled Adjunctive Therapy to Prevent Vancomycin Resistance Evolution: Toward Nano-Anti-Antibiotics
Authors: Roya Koshani, Shang-Lin Yeh, Landon G Vom Steeg, Mica L Pitcher, Joy Kirigo, Sean Leconey, Zeming He, Min Ju Park, Robert J Woods, Andrew F Read, Amir Sheikhi
Journal: Biomaterials (2025)
Tissue nanotransfection-based endothelial PLCγ2-targeted epigenetic gene editing in vivo rescues perfusion and diabetic ischemic wound healing
Authors: Sumit S Verma, Chandan K Sen, Rajneesh Srivastava, Surya C Gnyawali, Parul Katiyar, Ajay K Sahi, Manishekhar Kumar, Yashika Rustagi, Sheng Liu, Diksha Pandey, Ahmed S Abouhashem, Leila Nw Fehme, Sedat Kacar, Sujit K Mohanty, Julie Faden-McCormack, Michael P Murphy, Sashwati Roy, Jun Wan, Mervin C Yoder, Kanhaiya Singh
Journal: Molecular Therapy (2025)
PBAE-PEG based lipid nanoparticles for lung cell-specific gene delivery
Authors: Bingxin Liu, Yamato Sajiki, Nicole Littlefield, Yongan Hu, William D Stuart, Anusha Sridharan, Xuemei Cui, Matthew E Siefert, Koichi Araki, Assem G Ziady, Donglu Shi, Jeffery A Whitsett, Maeda Yutaka
Journal: Molecular Therapy (2025)
Prospective analysis of biomarkers associated with successful faecal microbiota transplantation in recurrent Clostridioides difficile Infection
Authors: Silvia Vázquez-Cuesta, María Olmedo, Martha Kestler, Ana Álvarez-Uría, Sofía De la Villa, Luis Alcalá, Mercedes Marín, Sara Rodríguez-Fernández, Celia Sánchez-Martínez, Patricia Muñoz, Emilio Bouza, Elena Reigadas
Journal: Clinical Microbiology and Infection (2025)
Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque psoriasis: Long-term results from the BE RADIANT phase 3b trial open-label extension period
Authors: Richard B Warren, Mark Lebwohl, Diamant Thaçi, Melinda Gooderham, Andreas Pinter, Carle Paul, Paolo Gisondi, Balint Szilagyi, Katy White, Delphine Deherder, Fabienne Staelens, Jérémy Lambert, Bruce Strober
Journal: British Journal of Dermatology (2025)

Abstract Background Overexpression of interleukin (IL)-17A and IL-17F significantly influences psoriasis pathology. Until recently, biologics targeting IL-17A alone, like secukinumab, were used to treat psoriasis. Bimekizumab is a monoclonal IgG1 antibody that targets both IL-17A and IL-17F. BE RADIANT was the first phase 3 study to investigate switching from selective inhibition of IL-17A to dual inhibition of IL-17A and IL-17F. Bimekizumab has previously shown superior achievement of complete skin clearance (PASI 100) versus secukinumab through 48 weeks. Switching from secukinumab to bimekizumab resulted in improved clinical responses. Over 2 years, no new safety signals were observed. Objective To report 3-year efficacy and safety of bimekizumab in patients with moderate to severe plaque psoriasis receiving continuous bimekizumab, or switching from secukinumab after 1 year. Methods The BE RADIANT phase 3b randomised controlled trial had a 48-week double-blinded period, in which patients received bimekizumab (320 mg every 4 weeks [Q4W]), or secukinumab (300 mg weekly to Week 4, then Q4W). At Week 16, bimekizumab-randomised patients underwent re-randomisation to receive Q4W or Q8W maintenance dosing. From Week 48 onwards (open-label extension), all received bimekizumab. Results 336 bimekizumab- and 318 baseline secukinumab-randomised patients entered the open-label extension. Among these, more bimekizumab-randomised patients achieved PASI 100 (modified non-responder imputation) at Year 1 (74.9%) versus secukinumab-randomised patients (52.8%). PASI 100 response rates were maintained over 3 years in bimekizumab-treated patients (68.8%) and increased in secukinumab-randomised patients switching to bimekizumab (68.8%). Bimekizumab was well-tolerated to 3 years. In patients receiving ≥1 bimekizumab dose, the most common treatment-emergent adverse events (TEAEs) over 3 years were nasopharyngitis, oral candidiasis, and upper respiratory tract infection (exposure adjusted incidence rates: 12.2, 10.0, and 5.5/100 patient-years, respectively). Rates of TEAEs of interest, including serious infections, inflammatory bowel disease, and suicidal ideation and behaviour, did not increase with longer exposure to bimekizumab from 1 to 3 years. Conclusion Over two-thirds of bimekizumab-randomised patients and those switching from secukinumab to bimekizumab achieved and maintained complete skin clearance over 3 years of treatment. Over 3 years, bimekizumab was well-tolerated, and TEAE rates did not increase with longer exposure.
Dual Oxygen Supply System of Carbon Dot-Loaded Microbubbles with Acoustic Cavitation for Enhanced Sonodynamic Therapy in Diabetic Wound Healing
Authors: Guangrong Ma, Ke Cheng, Xue Wang, Yiqing Zeng, Chenlu Hu, Luying He, Zhan Shi, Hengwei Lin, Tao Zhang, Shan Sun, Pintong Huang
Journal: Biomaterials (2025)
Growing old as a trans woman sex worker: A scoping review
Authors: Mariana Melo, Alexandra Oliveira, Sara Isabel Magalhães
Journal: International Journal of Transgender Health (2025)

Background and objectives Although older trans women sex workers have been denied access to the support structures available in the community and although their vulnerability is known to increase as they age, little research has been conducted on this subject. This scoping review aimed to address gaps in the literature by collecting data from the peer-reviewed and grey literature that deal with the experiences and characteristics of older trans women sex workers.